Search the web
Welcome, Guest
[Sign Out, My Account]
Morningstar_Inc.

Friday, July 25 2014 3:00am ET - U.S. Markets open in 6 hours and 30 minutes.
Industry Center
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Tools
·Industry Index
·News by Industry
·Leaders & Laggards
·Industry Browser
  
Today's Top Performing Industry
Biotechnology
Composite Value: 1319.6
Today's Change: +16.10%
S&P 500: +0.05%
chart for
[Biotechnology (^YHOh788)]
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer
30 minutes ago (PR Newswire)
WHIPPANY, N.J. and SOUTH SAN FRANCISCO, Calif., July 25, 2014 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (AMGN), today announced that an investigational Phase 3 trial of NEXAVAR® (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). The study, called RESILIENCE, evaluated the efficacy and safety of sorafenib in combination with capecitabine, an oral chemotherapeutic agent, compared to placebo plus capecitabine, in patients with HER2-negative breast cancer who are resistant to or have failed prior taxane therapy, and resistant to or failed anthracycline or for whom further anthracycline therapy is not indicated. Based on initial review of the data, the types of adverse events observed were generally comparable with those known for either sorafenib or capecitabine. "We are disappointed that the trial did not show an improvement in progression-free survival in patients with advanced breast cancer," said Dr. Joerg Moeller, Member of the Bayer HealthCare Executive Committee and Head of Global Development. "While the primary endpoint of this trial was not met, the trial results do not affect the currently approved indications for NEXAVAR.
Today's Industry Highlights
Top Performing Industries% Change
Biotechnology +16.10%
Internet Service Providers +2.86%
Auto Parts Stores +2.39%
Sporting Goods Stores +2.29%
Paper & Paper Products +2.07%
View Leaders & Laggards...
Worst Performing Industries % Change
Toy & Hobby Stores -11.11%
Sporting Activities -2.42%
Regional Airlines -2.02%
Heavy Construction -1.82%
Lumber, Wood Production -1.70%
View Leaders & Laggards...
  
Locate Industry by Company
Enter Symbol:
Leaders & Laggards
Highest Dividend Yield
Medical Practitioners 22.30%
More...
Highest Market Capitalization
Auto Manufacturers - Major $1890780.0 B
More...
Highest Net Profit Margin (mrq)
Closed-End Fund - Equity 82.60%
More...
Highest P/E Ratio
General Entertainment 316.00
More...
Highest Return on Equity
Auto Parts Stores 79.90%
More...


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2014 Morningstar, Inc. All Rights Reserved. Company information © 2014 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2014, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?